Skip to main content
Log in

Individual Case Safety Reports —How to Determine the Onset Date of an Adverse Reaction

A Survey

  • Short Communication
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background: The building blocks of a pharmacovigilance system depend primarily on good quality individual case safety reports (ICSRs), which are stand-alone summaries describing one or more suspected adverse reactions that occur while a subject is taking either an investigational or marketed medicinal product and may require expedited reporting to regulatory authorities. For regulatory reporting purposes, the information of an ICSR is usually captured on forms such as MedWatch 3500/3500A, CIOMS I, Vaccine Adverse Event Report System (VAERS) or Adverse Events Following Immunization (AEFI). ICSRs that are sent electronically must meet the standards for electronic transmission specified in the International Conference on Harmonisation (ICH) E2B (R2) guideline. In filling out these regulatory forms, there are some areas of ambiguity. One of these is what the ‘date of event’ (MedWatch) or ‘reaction onset date’ (CIOMS) is interpreted to be.

Objective: The aim of the survey was to determine the uniformity of responses for the onset date of an adverse reaction.

Methods: A pilot and three surveys of pharmacovigilance professionals were undertaken between February and July 2009 to determine the range of responses for the onset of an adverse reaction. A narrative of a subject admitted to hospital with a diagnosis of pneumonia was presented and the respondent was asked to pick the date of onset of the adverse reaction.

Results: The total number of respondents was 129. The results of the surveys indicated there was considerable variation in responses. These differences were based on different perspectives regarding the suspected adverse reaction. Some viewed the ‘reaction’ to be the first onset of signs and symptoms (even if nonspecific), others considered the onset of the reaction to be the date of the diagnosis, while others considered the date to be when the reaction became serious.

Conclusion: By means of a survey, we have illustrated an example of the variability of determining the onset date of a suspected adverse reaction, and recommend that a criterion for onset time, i.e. beginning of signs or symptoms of the event, or date of diagnosis, be chosen as the standard. Once decided, this information should be incorporated into the company’s case assessment documentation and staff appropriately trained, thus ensuring consistency across cases and minimizing the time spent in determining what date to use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical safety data management: definitions and standards for expedited reporting E2A. Geneva: ICH Secretariat, 2004 Oct [online]. Available from URL: http://www.ich.org/products/guidelines/efficacy/article/efficacyguidelines.html [Accessed 2011 Jan 21]

  2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Post-approval safety data management: definitions and standards for expedited reporting E2D. Geneva: ICH Secretariat, 2003 Nov [online]. Available from URL: http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html [Accessed 2011 Jan 21]

  3. CIOMS V. Current challenges in pharmacovigilance: pragmatic approaches. Geneva: Council for International Organizations of Medical Sciences, 2001

    Google Scholar 

  4. US Department of Health and Human Services, Food and Drug Administration. Form voluntary reporting (form FDA 3500) [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm [Accessed 2011 Jan 21]

  5. US Department of Health and Human Services, Food and Drug Administration. Form mandatory reporting (form FDA 3500A) [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm [Accessed 2011 Jan 21]

  6. Council for International Organizations of Medical Sciences [online]. Available from URL: http://www.cioms.ch/form/frame_form.htm [Accessed 2011 Jan 21]

  7. US Department of Health and Human Services, Food and Drug Administration. Vaccine Adverse Event Reporting System (VAERS) [online]. Available from URL: https://vaers.hhs.gov/esub/index [Accessed 2011 Jan 21]

  8. Public Health Agency of Canada. Adverse events following immunization reporting form [online]. Available from URL: http://www.phac-aspc.gc.ca/im/aefi-form-eng.php [Accessed 2011 Jan 21]

  9. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Revision of the ICH guideline on clinical safety data management data element for transmission of individual safety reports E2B (R2). Geneva: ICH Secretariat, 2005 May [online]. Available from URL: http://www.ich.org/products/guidelines/efficacy/article/efficacyguidelines.html [Accessed 2011 Jan 21]

  10. Center for Drug Evaluation and Research, Food and Drug Administration. The clinical impact of adverse event reporting [online]. Available from URL: http://www.fda.gov/downloads/Safety/MedWatch/UCM168505.pdf [Accessed 2011 Jan 21]

  11. Kelly WN, Barnes J, Bergman U, et al. Guidelines for submitting adverse reports for publication. Drug Saf 2007; 30: 367–73

    Article  PubMed  Google Scholar 

  12. US FDA. Patient profile viewer: notice of pilot project [online]. Available from URL: http://www.federalregister.gov/articles/2001/12/10/01-30430/patient-profile-viewer-notice-of-pilot-project [Accessed 2011 Jan 21]

  13. Edwards B, Prabhakar U. Postmarketing safety surveillance: issues with data collection for postmarketing pharmacovigilance. Pharm Med 2010; 24(6): 1–6

    Google Scholar 

  14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Pharmaceutical development Q8 (R2). Geneva: ICH Secretariat 2009 Aug [online]. Available from URL: http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html [Accessed 2011 Jan 21]

Download references

Acknowledgements

The authors certify no funding has been received for the preparation of this manuscript or to conduct this survey. Dr Michael Klepper, an independent drug safety/pharmacovigilance consultant, and Dr Brian Edwards, a pharmacovigilance consultant with NDA Regulatory Science Ltd, both consult to the pharmaceutical industry.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael J. Klepper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klepper, M.J., Edwards, B. Individual Case Safety Reports —How to Determine the Onset Date of an Adverse Reaction. Drug-Safety 34, 299–305 (2011). https://doi.org/10.2165/11588490-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11588490-000000000-00000

Keywords

Navigation